[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649565":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":26,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":26,"overallStatus":78,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HW243040 group","EXPERIMENTAL","Single or multiple dose of HW243040 will be administered orally.",[13],"Drug: HW243040",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Single or multiple dose of placebo will be administered orally.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","HW243040","HW243040 will be administered orally as a tablet.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo will be administered orally as a tablet.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Lifei Liu","CONTACT","86-027-87173753","liulifei@renfu.com.cn",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The Third Xiangya Hospital of Central South University","Changsha","Hunan","410013","China","CN",{"type":46,"coordinates":47},"Point",[48,49],112.97087,28.19874,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":26,"email":55},"Guoping Yang","86-0731-89918665","ygp9880@163.com",{"type":57,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100649565","phase-1-a-study-of-hw243040-in-healthy-participants-100649565",false,"NCT07737496","A Study of HW243040 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Single-Center, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW243040 in Healthy Participants","Inclusion Criteria:\n\n* Informed consent must be obtained\u002Fsigned prior to trial participation.\n* Aged between 18 and 55 years old, both healthy males and females are eligible.\n* Female participates must have a body weight of ≥ 45 kg and male participates ≥ 50 kg, with a body mass index (BMI) ranging from 19 to 26 kg\u002Fm\\^2.\n\nExclusion Criteria:\n\n* History or presence of any clinically severe disorders of urinary, cardiovascular, endocrine, nervous, gastrointestinal, respiratory, hematologic, immune systems, psychiatric illnesses or metabolic abnormalities; or other conditions judged by the Investigator to confound trial outcomes, e.g., intestinal diseases (irritable bowel syndrome), urinary tract infections.\n* History of malignant tumors (except for cancer with confirmed cure or remission for ≥5 years, radically resected basal or squamous cell skin cancer, carcinoma in situ of the cervix, and resected colonic polyps).\n* Any conditions or diseases that, in the Investigator's judgment, may affect the absorption, metabolism and\u002For excretion of the investigational product.\n* History of drug abuse or dependence.\n* Hypersensitivity to any ingredient of the study drug，or history of allergic disorders or allergic diathesis.\n* Any other condition that, in the opinion of the investigator, renders the participant unsuitable to participate in the study.",true,"ALL","18 Years","55 Years",{"count":70,"type":71},98,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.",[77],"Healthy","NOT_YET_RECRUITING","2026-07-29",{"date":81,"type":82},"2026-07-31","ACTUAL",{"date":84,"type":71},"2026-08-10",{"date":86,"type":71},"2027-05-31",{"name":5,"class":6},1]